Royalty Pharma has acquired 3 companies, including 2 in the last 5 years.
Royalty Pharma’s largest acquisition to date was in 2017, when it acquired TYSABRI for $2.9B. Royalty Pharma has acquired in 2 different US states. The Company’s most targeted sectors include life science (100%).
Join Mergr and gain access to Royalty Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the business services sector.
M&A Total Activity3
- M&A Buy Activity3
- Total Sectors Invested 1
- Total Countries Invested 1
- M&A Buy/Sell Connections 3
- M&A Advisors 3